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Hematopoietic stem cells (HSCs) have the ability 
to self-renew as well as to produce multiple lin-
eages of daughter cells throughout an animal’s life 
(Adams and Scadden, 2006; Kiel and Morrison, 
2008). Hematopoietic stem and progenitor cells 
(HSPCs) are thought to reside in specific niches, 
which are specialized microenvironments within 
the BM cavity (Calvi et al., 2003; Zhang et al., 
2003; Arai et al., 2004; Kiel et al., 2005; Stier et al., 
2005; Adams  and  Scadden,  2006;  Sugiyama   
et al., 2006; Kiel and Morrison, 2008; Lymperi 
et al., 2010). Niches consist of various cell types 
such as osteoblastic cells, vascular endothelial cells 
or reticular cells, and associated factors such as 
angiopoietin1, N-cadherin, osteopontin, and 
Cxcl12 (Calvi et al., 2003; Zhang et al., 2003;   
Arai et al., 2004; Kiel et al., 2005; Stier et al., 
2005; Adams and Scadden, 2006; Sugiyama   
et al., 2006; Kiel and Morrison, 2008; Lymperi 
et al., 2010). A functional BM is reportedly re-
quired for HSPC mobilization to the periphery 
from BM cavities (Katayama et al., 2006). Thus, 
these cavities are considered crucial for HSPC 
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Hematopoietic stem cells (HSCs) are maintained in a specific bone marrow (BM) niche in 
cavities formed by osteoclasts. Osteoclast-deficient mice are osteopetrotic and exhibit 
closed BM cavities. Osteoclast activity is inversely correlated with hematopoietic activity; 
however, how osteoclasts and the BM cavity potentially regulate hematopoiesis is not well 
understood. To investigate this question, we evaluated hematopoietic activity in three 
osteopetrotic mouse models: op/op, c-Fos-deficient, and RANKL (receptor activator of 
nuclear factor kappa B ligand)-deficient mice. We show that, although osteoclasts and, by 
consequence, BM cavities are absent in these animals, hematopoietic stem and progenitor 
cell (HSPC) mobilization after granulocyte colony-stimulating factor injection was compa-
rable or even higher in all three lines compared with wild-type mice. In contrast, osteoprotegerin- 
deficient mice, which have increased numbers of osteoclasts, showed reduced HSPC 
mobilization. BM-deficient patients and mice reportedly maintain hematopoiesis in extra-
medullary spaces, such as spleen; however, splenectomized op/op mice did not show  
reduced HSPC mobilization. Interestingly, we detected an HSC population in osteopetrotic 
bone of op/op mice, and pharmacological ablation of osteoclasts in wild-type mice did  
not inhibit, and even increased, HSPC mobilization. These results suggest that osteoclasts 
are dispensable for HSC mobilization and may function as negative regulators in the  
hematopoietic system.
©  2011  Miyamoto  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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These mice lack a BM cavity and exhibit impaired osteo-
clastogenesis (Fig. 1 A). Previously, the cell cycle–specific cyto-
toxic agent 5-fluorouracil (5-FU), which is used in chemotherapy, 
has been used to evaluate HSC function because HSCs are resis-
tant to 5-FU–induced cell death as a result of their quiescence 
(Cheng et al., 2000; Miyamoto et al., 2007). op/op and wild-type 
mice were serially treated with 5-FU, and we found that op/op 
mice were lethally susceptible to 5-FU treatment compared with 
control op/+ mice (Fig. 1 B), suggesting that osteoclasts and BM 
cavities are required to maintain HSCs.
To confirm roles of osteoclasts and BM cavities in the   
hematopoietic system, op/op mice were serially treated with   
G-CSF and HSPCs mobilization was analyzed (Fig. 1, C–E). 
Because a functional BM niche or osteoclasts are reportedly 
required to mobilize HSPCs to the periphery from the BM 
(Heissig et al., 2002; Katayama et al., 2006; Kollet et al., 
2006), we predicted that op/op mice would show inhibited 
HSPC  mobilization  after  G-CSF  injection.  However,  we 
found that mobilization of the HSC-enriched fraction (lineage 
negative, c-Kit positive, and Sca1 positive [LSK]) to peripheral 
blood, as analyzed by flow cytometry, was induced to levels 
even higher in op/op mice than in control littermate mice 
(op/+; Fig. 1, C and D). HSPCs mobilized in op/op mice were 
functional: colony-forming assays showed that greater numbers 
of colonies formed from the peripheral blood of G-CSF–
treated op/op mice than from that of wild-type mice (Fig. 1 E). 
This observation suggests that op/op mice accumulate a greater 
number of HSCs than do wild-type mice, and that neither BM 
cavities nor osteoclasts are required for HSC maintenance and 
mobilization and may even be inhibitory to the process.
HSPC mobilization is induced  
in c-Fos– and RANKL-deficient mice
To confirm these findings, c-Fos–deficient mice, which are 
also osteoclast deficient and lack BM cavities, were analyzed 
(Fig. S1 A). We observed that c-Fos–deficient mice were less 
susceptible to serial 5-FU treatment than were op/op mice 
(Fig. S1 B), suggesting that M-CSF, rather than BM cavities 
and osteoclasts, is required to resist 5-FU treatment. Indeed, 
injection of M-CSF into op/op mice rescued mice from a 
lethal response to 5-FU (Fig. S1 C). M-CSF regulates osteo-
clast formation as well as macrophage differentiation and 
innate immunity (Miyamoto et al., 2001; Chitu and Stanley, 
2006). In wild-type mice, M-CSF concentration in sera was 
significantly up-regulated after 5-FU treatment, suggesting   
a protective role for M-CSF against myelosuppression in-
duced by chemotherapy (Fig. S1 D). In fact, both Gram-
positive and -negative bacteria were detected in multiple 
organs of 5-FU–treated op/op mice (Fig. S1 E and not de-
picted). These results indicate that by inducing macrophages, 
M-CSF likely plays a critical role in resistance to hemato-
poietic suppression after 5-FU treatment. They also suggest 
that  serum  M-CSF  concentrations  should  be  carefully 
monitored during myelosuppressive chemotherapies to pre-
vent opportunistic infections.
maintenance and mobilization; however, the impact of loss of 
BM cavities on the hematopoietic system remains unclear.
BM cavities are formed by osteoclasts, which are bone re-
sorbing multinuclear cells, and loss of osteoclasts results in loss   
of BM cavities (Yoshida et al., 1990; Grigoriadis et al., 1994; 
Kong et al., 1999). Various factors, such as M-CSF, c-Fos, and 
receptor activator of nuclear factor kappa B ligand (RANKL), 
are reportedly essential for osteoclastogenesis; mutational inacti-
vation or genetic ablation of these molecules results in a lack   
of osteoclast differentiation and consequent defects in BM cav-
ity formation, a condition termed osteopetrosis in which BM 
cavities are filled with bone (Yoshida et al., 1990; Grigoriadis   
et al., 1994; Kong et al., 1999). Osteoprotegerin (OPG) is a 
decoy receptor of RANKL that inhibits osteoclastogenesis   
(Bucay et al., 1998; Mizuno et al., 1998). Although bone pheno-
types of op/op, c-Fos–deficient, RANKL-deficient, and OPG-
deficient mice have been described, hematopoietic phenotypes 
in these mice have not yet been fully characterized. Clinically, 
osteoclastic activity increases after serial G-CSF injection admin-
istered before peripheral HSC implantation (Takamatsu et al., 
1998; Watanabe et al., 2003), and such activity is reportedly re-
quired to drive HSPCs from the marrow to the periphery   
(Kollet et al., 2006). Therefore osteoclast-deficient mice, which 
lack a BM niche, are predicted to be defective in hematopoiesis 
as a result of impaired osteoclast activity required to mobilize 
HSPCs to the periphery. Indeed, osteopetrotic patients, as well as 
animal models, reportedly show extramedullary hematopoiesis in 
the spleen (Freedman and Saunders, 1981; Lowell et al., 1996).
Osteoclastogenesis is accelerated with age, resulting in de-
creased bone mass (Manolagas and Jilka, 1995; Teitelbaum, 
2007). Hematopoietic activity also decreases with age (Geiger 
and Rudolph, 2009; Waterstrat and Van Zant, 2009), suggest-
ing that osteoclast activity is inversely correlated with hemato-
poietic activity; however, precise roles of osteoclasts in regulating 
hematopoiesis are largely unknown.
In this paper, we show that HSPCs are maintained even in 
osteopetrotic animals and that they are mobilized to the periph-
ery after G-CSF stimulation, indicating that osteoclasts and BM 
cavities are both dispensable for HSPC maintenance and egress 
to the periphery. Pharmacological inhibition of osteoclastic ac-
tivity did not inhibit but rather stimulated HSPC mobilization. 
Splenectomy of op/op mice increased HSPC mobilization, sug-
gesting that spleen is not the primary tissue that maintains HSCs 
in osteopetrotic animals. HSCs were also detected in the osteo-
petrotic bone. OPG-deficient mice, which show increased osteo-
clastic activity, exhibited reduced HSPC mobilization. Thus, 
accelerated osteoclastic activity decreases both bone mass and 
hematopoietic activity, and both can be manipulated pharma-
cologically in vivo.
RESULTS AND DISCUSSION
HSPCs are maintained and mobilized in op/op mice
To determine whether loss of the BM niche and osteoclasts 
influences hematopoiesis, we analyzed osteopetrotic op/op mice, 
which carry a loss-of-function mutation in M-CSF, a cyto-
kine essential for osteoclast differentiation (Yoshida et al., 1990). JEM Vol. 208, No. 11  2177
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Impaired HSPC mobilization in OPG-deficient mice
To further explore the role of BM cavities and osteoclasts in 
HSC  maintenance,  HSPC  mobilization  in  OPG-deficient 
mice was analyzed by serial G-CSF injection (Fig. 3). OPG is 
a decoy receptor for RANKL and therefore acts as a RANKL 
inhibitor (Bucay et al., 1998; Mizuno et al., 1998). OPG-
deficient mice show severe osteoporosis as a result of acceler-
ated osteoclastogenesis (Fig. 3, A and B). As expected, in 
contrast to osteoclast-deficient osteopetrotic mice, reduced 
HSPC mobilization was seen in OPG-deficient mice, as in-
dicated by flow cytometry and colony-forming assays, com-
pared with wild-type mice (Fig. 3, C–E). Furthermore, long- 
term competitive repopulation assays using mobilized cells   
from CD45.2+ op/op, c-Fos-deficient, or RANKL-deficient   
mice versus CD45.1+ BM competitors showed higher chi-
merism relative to that induced using mobilized cells from 
control mice (Fig. 3 F). In contrast, mobilized cells from 
OPG-deficient mice induced lower chimerism than those 
from wild-type mice (Fig. 3 F). CD45.2 reconstitution was 
multilineage; CD45.2 reconstitution from mobilized donor 
RANKL-deficient mice are also osteoclast deficient and 
lack BM cavities (Fig. S1 F). Interestingly, increased HSPC 
mobilization after serial G-CSF treatment was observed in 
both c-Fos–deficient and RANKL-deficient mice (Fig. 2), as 
it was in op/op mice, supporting the idea that osteoclasts and 
BM cavities are not required to maintain HSCs.  Young female 
PTP-knockout mice reportedly show a mild loss of osteo-
clast function but exhibit a BM cavity and impaired HSPC 
mobilization  by  G-CSF  (Kollet  et  al.,  2006). The  three   
osteoclast- and BM cavity–deficient animal models evaluated 
in this study did not show defective HSPC mobilization after 
G-CSF treatment, suggesting that the function of osteoclasts 
in driving HSCs to the periphery is biphasic or BM cavity 
dependent. In wild-type mice, the number of osteoclasts re-
portedly does not increase during G-CSF treatment, but only 
after cessation of treatment (Takamatsu et al., 1998; Christopher 
and Link, 2008; Winkler et al., 2010), also suggesting that   
osteoclast loss likely does not affect HSPC mobilization in 
response to G-CSF treatment. All three osteopetrotic animal 
models show increased mobilization of HSPCs to the periph-
ery without G-CSF administration (Figs. 1 and 2), suggesting 
that steady-state levels of circulating HSPCs are increased in 
these animals.
Figure 1.  op/op mice are osteopetrotic and exhibit 
increased numbers of HSPCs. (A) Microradiographical 
analysis of femoral bones of 8-wk-old op/op and control 
(op/+) bone. Representative micro-CT data in three indepen-
dent op/op or op/+ mouse bones are shown. Bars, 1 mm.  
(B) 150 mg/kg 5-FU was injected into the peritoneal cavity of 
8-wk-old op/op (n = 5) and littermate control (op/+; n = 5) 
mice on days 0 and 7, and the survival rate after 5-FU injec-
tion was analyzed. (C–E) 250 µg/kg/d G-CSF or PBS was in-
jected subcutaneously into 8–12-wk-old op/op and control 
(op/+) mice daily for 5 d (n = 3 for each group). Peripheral 
blood was collected, and the frequency of the HSC fraction 
(LSK; C and D) and CFU-C (E) were analyzed. (C) Representa-
tive flow cytometric pattern of peripheral blood. Cells were 
gated on lineage (CD3, B220, TER119, Mac1, and Gr1)-nega-
tive cells. Data represent the mean LSK frequency (%) ± SD 
in peripheral blood (*, P < 0.051; D) and CFU-C ± SD in 1 ml 
peripheral blood (*, P < 0.01, n = 9 for each group; E).  
Representative data of three independent experiments  
are shown (B–E).
Figure 2.  c-Fos–deficient and RANKL-deficient 
mice show elevated HSPC pools. (A–F) 250 µg/kg/d 
G-CSF or control PBS was injected subcutaneously 
into 8–12-wk-old c-Fos–deficient (c-Fos KO; n = 5 
for each group) or RANKL-deficient (RANKL KO; n = 5 
for each group) mice or into respective control litter-
mates (wild-type [WT]; n = 5 for each group) daily for 
5 d. Peripheral blood was collected, and the propor-
tion of HSCs (A, B, D, and E) and CFU-C (C and F) 
were analyzed. (A and D) Representative flow cytom-
etry pattern of peripheral blood. Cells were gated on  
lineage-negative cells. Data represent the mean LSK 
frequency (%) ± SD in peripheral blood (*, P < 0.01,  
n = 5 for each group; B and E) and mean CFU-C ± SD 
in 1 ml peripheral blood (*, P < 0.01, n = 6 for each 
group; C and F). Representative data from one of three  
independent experiments are shown (A–F).2178 Osteoclast-independent HSC regulation | Miyamoto et al.
osteomacs  and  CD11b+F4/80+Ly6-G+  macrophages  were 
detected in osteoclast-deficient c-Fos–deficient mice, we do 
not consider F4/80+ cells to be osteoclasts. Indeed, F4/80 is 
reportedly not expressed in osteoclasts (Quinn et al., 1999).
The spleen is not the primary tissue that maintains HSPCs  
in op/op mice
Hematopoiesis in osteopetrotic mice reportedly occurs in 
extramedullary spaces, such as spleen (Lowell et al., 1996). 
Indeed, a greater proportion of LSK cells was seen in the 
HSPCs was observed in CD11b+ myeloid, B220+ B cell, and 
CD3+ T cell recipient lineages (Fig. S2). Thus, osteoclasts 
and BM cavities appear to antagonize HSC maintenance.
F4/80+ osteomacs are defective in op/op mice but appear 
normal in c-Fos– or OPG-deficient mice
Recently, it was reported that F4/80+ macrophages, termed 
osteomacs, reside in the endosteal (Chang et al., 2008) where 
they support osteoblast function, thereby contributing to   
retain HSCs in the BM niche (Winkler et al., 2010). Thus, 
increased  HSPC  mobilization  seen  in  op/op  mice  after   
G-CSF injection could be a result of reduced levels of osteo-
macs. Indeed, we observed fewer F4/80+ osteomacs in op/op  
mice, although their levels in c-Fos–deficient and RANKL-
deficient mice were similar to those observed in wild-type 
mice (Fig. 4). These observations suggest that osteomac re-
duction is not a common property of osteopetrotic mice, all 
of which show increased HSPC mobilization after G-CSF 
administration. CD11b+F4/80+Ly6-G+ macrophages, which 
also reportedly inhibit HSPC mobilization into the periph-
eral blood, are reduced after G-CSF treatment in wild-type 
mice (Winkler et al., 2010). However, like osteomacs, the 
CD11b+F4/80+Ly6-G+ macrophage population was reduced 
in op/op mice compared with wild-type mice, but such a re-
duction was not seen in c-Fos–deficient mice (Fig. S3 A). In 
OPG-deficient mice, osteomac and CD11b+F4/80+Ly6-G+ 
macrophage levels were similar to those seen in wild-type 
mice (Fig. 4 and Fig. S3 A). These results suggest that both of 
these cell types are M-CSF dependent and are deficient in the 
op/op model of osteopetrotic mice, but that this deficiency is 
not likely be the cause of increased mobilization of HSPCs 
seen in osteopetrotic animals. A more likely explanation is 
that HSPC mobilization seen in all osteopetrotic models is a 
result of loss of osteoclasts and BM cavities. Because F4/80+ 
Figure 3.  OPG-deficient mice are osteoporotic and have 
reduced HSPC pools. (A and B) BMD assays and microradiogra-
phy analysis were undertaken in femurs of 8–12-wk-old OPG-
deficient (OPG KO; n = 5) and wild-type (WT; n = 5) mice using 
dual-energy x-ray absorptiometry (mg/cm2; A) and micro-CT  
(B), respectively. BMD was shown in 20 longitudinal divisions of 
femurs. Bars, 1 mm. (C–E) 250 µg/kg/d G-CSF was injected sub-
cutaneously into OPG-deficient (OPG KO; n = 5) and wild-type 
control (WT; n = 5) mice daily for 5 d. Peripheral blood was then 
collected, and the frequency of the LSK fraction (C and D) and 
CFU-C (E) were analyzed by flow cytometry and colony-forming 
assays, respectively. (C) Representative flow cytometry pattern 
of peripheral blood cells. Cells were gated with lineage-negative 
cells. Data represent the mean LSK frequency (%) ± SD in pe-
ripheral blood (*, P < 0.01, n = 5; D) and CFU-C ± SD in 1 ml 
peripheral blood (*, P < 0.01, n = 12; E). (F) 250 µg/kg/d G-CSF 
was injected subcutaneously into OPG-deficient (OPG KO),  
c-Fos–deficient (c-Fos KO), RANKL-deficient (RANKL KO), and 
littermate control mice daily for 5 d. Peripheral blood was  
collected from each mouse and transplanted into lethally irradiated Ly5.1 recipient mice with BM competitors isolated from Ly5.1 mice. Peripheral blood 
of recipient mice was collected after 3 mo of transplantation and stained with PE-conjugated anti-CD45.1 and FITC-conjugated anti-CD45.2, and leuko-
cyte chimerism was determined by FACS. Data represent the mean CD45.2+ frequency (%) ± SD in peripheral blood (*, P < 0.01; **, P < 0.05, n = 8). Repre-
sentative data of two (A, B, and F) and three (C, D, and E) independent experiments are shown.
Figure 4.  Osteomac levels are reduced in op/op but not c-Fos-
deficient mice. Paraffin specimens of op/op, c-Fos-deficient (c-Fos KO), 
RANKL-deficient (RANKL KO), OPG-deficient (OPG KO), and control mouse 
femoral bones were stained with Alexa Fluor 488–conjugated anti-F4/80 
antibody and observed under a confocal microscope. TOTO3 served as a 
nuclear stain. Arrowheads indicate F4/80-positive osteomacs. Representa-
tive data of three independent experiments are shown. Bars, 100 µm.JEM Vol. 208, No. 11  2179
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Osteoclast-inhibiting agents increase HSPC mobilization  
in wild-type mice
Finally, we asked whether blocking osteoclast function or dif-
ferentiation pharmacologically would inhibit or enhance   
hematopoietic  activity  in  wild-type  mice.  Wild-type  mice 
were pretreated with bisphosphonate (alendronate) or vehicle 
(PBS), and HSPC mobilization after serial G-CSF injection 
was analyzed (Fig. 6). Bisphosphonate treatment significantly 
increased bone mass (Fig. 6, A and B), and, interestingly, mo-
bilization of HSPCs as determined by a colony-forming assay 
was highly induced in bisphosphonate- compared with vehicle- 
treated  mice  (Fig.  6  C).  Thus,  bisphosphonate  therapy   
increased bone mass and up-regulated HSPC mobilization. 
Similar phenotypes were detected in mice treated with neu-
tralizing RANKL antibody compared with isotype-matched 
control antibody-treated mice (Fig. 6, D–F). Thus our results 
demonstrate that HSCs can be expanded pharmacologically. 
Treatment  with  zoledronate,  another  bisphosphonate,  also   
reportedly increased HSPC mobilization in response to G-CSF 
(Winkler et al., 2010), further suggesting that bisphosphonate, 
neutralizing RANKL antibody, or other osteoclast inhibitors 
might serve as adjuvants to increase HSPC mobilization.
Collectively, our results challenge the dogma that BM 
cavity–deficient animals cannot maintain HSCs and raises the 
question of why mammalian and avian species developed BM 
cavities. Although the density of osteopetrotic bones in op/op 
mice was greater than that seen in controls (Fig. S5 A), strength 
spleen of op/op mice than in control (op/+) mice (Fig. S3,   
B and C). Thus, we removed the spleen from op/op mice 
and treated those mice with G-CSF serially to analyze HSPC 
mobilization (Fig. 5). Interestingly, HSPC mobilization was 
induced  or  even  significantly  higher  in  splenectomized   
op/op mice compared with sham-operated op/op mice (Fig. 5). 
These data suggest that HSCs are maintained in tissues other 
than spleen in osteoclast-deficient osteopetrotic mice. Inter-
estingly, we found that bone tissues in osteoclast-deficient 
mice contained small spaces where c-Kit–positive hemato-
poietic cells are located (Fig. S4 A). Thus, hematopoiesis may 
be maintained in bone, even in osteopetrotic mice. In fact, 
flow  cytometry  analysis  revealed  an  HSC-enriched  LSK 
population in osteopetrotic bones of op/op mice (Fig. S4 B), 
and these cells were shown to be functional by an LTC-IC 
assay (not depicted). These results indicate that HSCs are 
maintained in bones of osteopetrotic mice, that increased 
bone mass as a result of impaired osteoclastogenesis may in-
crease functionality of the HSC niche, and that osteoclasts 
could be a therapeutic target to expand HSCs as well as bone 
mass. Bones are formed by osteoblasts, and osteoblasts re-
portedly express various niche factors such as angiopoietin 1, 
osteopontin,  Cxcl12,  and  KitL  (Arai  et  al.,  2004;  Stier   
et al., 2005; Adams and Scadden, 2006; Katayama et al., 
2006). We found that these niche factors were expressed in 
osteopetrotic bones of op/op, c-Fos–deficient, and RANKL- 
deficient mice (unpublished data).
Figure 5.  HSCs do not accumulate in the 
spleen of op/op mice. Splenectomy or sham 
surgery was performed on 8–12-wk-old op/op 
(n = 5 for each group) and control (op/+; n = 5 
for each group) mice. 7 d later, mice were 
injected with 250 µg/kg/d G-CSF daily for 5 d, 
and mobilization of HSCs to peripheral blood 
was analyzed using flow cytometry and  
colony-forming assays. (A) Representative 
flow cytometry pattern of peripheral blood 
after G-CSF injection (n = 5 for each group). Cells were gated on lineage-negative cells. (B and C) Data represent the mean LSK frequency (%) ± SD in 
peripheral blood (*, P < 0.01, n = 5 for each group; B) and mean CFU-C ± SD in 1 ml peripheral blood (*, P < 0.01, n = 5 for each group; C). Representative 
data of three independent experiments are shown.
Figure 6.  Pharmacological inhibition of osteo-
clasts increases bone mass and expands the HSC 
pool in wild-type mice. (A–C) Wild-type mice were 
treated with 5 mg per mouse of alendronate (bisphos-
phonate; n = 5) or vehicle (PBS; n = 5) daily for 14 d 
and then injected with 250 µg/kg/d G-CSF daily for five 
more days. Mice were assessed for BMD (A), micro-
radiography (B), and HSC mobilization in peripheral blood 
(C; **, P < 0.05, n = 5). Bar, 1 mm. (D and E) Wild-type 
mice were treated with 5 or 2.5 mg/kg of neutralizing 
antibody against RANKL (RANKL Ab; n = 5) or isotype 
control antibody (ISO; n = 5) 14 and 1 d before G-CSF 
injection, respectively. Mice were then injected with 
250 µg/kg/d G-CSF daily for 5 d, and BMD (D), micro-
radiography (E), and mobilization of HSCs in peripheral blood (F; *, P < 0.01, n = 5) were analyzed. BMD was shown in 20 longitudinal divisions of femurs  
(A and D). Data represent mean CFU-C ± SD in 1 ml peripheral blood (C and F). Bars, 1 mm. Representative data of two independent experiments are shown.2180 Osteoclast-independent HSC regulation | Miyamoto et al.
IL-6, and rh erythropoietin (MethoCult GF M3434; STEMCELL Technolo-
gies) in 35-mm culture dishes (Falcon) and incubated at 37°C in 5% CO2. The 
number of CFU-Cs was determined on day 7 using a microscope (Olympus). 
FACS analysis was undertaken as described. For some experiments, Alendro-
nate or RANKL neutralizing antibody was administered. 5 µg alendronate/
mouse/d was injected subcutaneously for 14 d before G-CSF injection. 5 mg/kg 
RANKL neutralizing antibody (Oriental Yeast Co.) or isotype control anti-
body (BD) at 14 d and 2.5 mg/kg at 1 d before G-CSF injection was injected 
into the peritoneal cavity. For competitive repopulation assays, peripheral 
blood from individual CD45.2+ mice was pooled, and 20 µl of pooled blood 
was mixed with 500,000 competitive BM cells from untreated CD45.1+ mice 
and injected intravenously into lethally irradiated CD45.1+ recipient mice.   
After 3 mo of transplantation, peripheral blood reconstitution in multiple 
lineages was determined by FACS using CD45.1 (A20), CD45.2 (104), Mac1 
(M1/70), CD3 (500A2), and B220 (RA3-6B2) antibodies (all BD).
Flow cytometry. mAbs (all BD) recognizing the following markers were 
used for flow cytometric analyses and cell sorting: c-Kit (2B8), Sca-1 (E13-
161.7), CD3 (500A2) B220 (RA3-6B2), TER-119 (Ly-76), Gr-1 (RB6-8C5), 
and Mac-1 (M1/70). A mixture of mAbs recognizing CD3, B220, TER-
119, Mac-1, or Gr-1 was used to identify lineage+ cells. Mature myeloid cells 
were stained with PEcy7-conjugated anti-CD11b (M1/70; eBioscience), 
Alexa  Fluor  488–conjugated  anti-F4/80  (CI:A3-1;  BioLegend),  and   
PE-conjugated anti–Ly6-G antibody (1A8; BD). Stained cells were analyzed 
on a FACS Aria2 machine (BD).
ELISA. Serum M-CSF levels were assayed using the Mouse M-CSF ELISA 
kit (R&D Systems), according to the manufacturer’s instructions.
Immunohistochemical  analysis. Frozen sections of op/op mice femoral 
bone that had not been decalcified were stained with goat anti–c-Kit antibody 
(AF1356; R&D Systems), followed by Alexa Fluor 488–conjugated donkey 
anti–goat antibody (Invitrogen) to detect HSCs and with TOTO3 (Invitro-
gen) to detect nuclei. Samples were observed under a fluorescence micro-
scope (IX70; Olympus). Paraffin sections of wild-type, op/op, c-Fos–deficient, 
and OPG-deficient mice femoral bone were stained with Alexa Fluor 488–
conjugated anti-F4/80 antibody (BioLegend) and TOTO3 as a nuclear stain 
and then observed under a confocal microscope (FV1000; Olympus).
Bone strength test. The femur was removed from mice and placed on the 
lower supports of a three point bending fixture with the anterior side facing 
up using an apparatus called the Bone Strength Tester MZ-500S (Maruto) 
installed with a load of 50 N. The span between the two lower supports was 
set at 6 mm. For all femoral specimens, the upper loading device was aligned 
to the center of the femoral shaft and the load was applied at a constant dis-
placement rate of 10 mm/min until breakage occurred.
Online supplemental material. Fig. S1 demonstrates the sensitivity of c-Fos–
deficient and op/op mice to 5-FU, and the bone phenotype of RANKL- 
deficient mice. Fig. S2 shows multilineage reconstitution of donor-derived 
cells in recipient mice. Fig. S3 demonstrates the frequency of the CD11b+F4/
80+Ly6-G+ macrophage population in wild-type, op/op, c-Fos–deficient, and 
OPG-deficient mice, and the frequency of LSK cells in op/op mouse spleen.   
Fig. S4 demonstrates the presence of HSCs in osteopetrotic bone. Fig. S5 shows 
osteopetrotic bone strength. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20101890/DC1.
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tests indicated that bones were more fragile than control bones 
(Fig. S5 B). Fractures were induced in osteopetrotic bones 
earlier and by lower energy than in control bones, based on 
constant displacement tests (Fig. S5, B and C). Osteopetrotic 
bone also showed reduced elasticity (Fig. S5 D). H/E staining 
indicated that op/op mouse bones were filled with trabecular 
bone and that mutants exhibited thinner cortical bones than 
did control mice (Fig. S5, E and F). Indeed, osteopetrotic pa-
tients suffer from frequent fractures (Landa et al., 2007). Thus 
bones likely developed not only to maintain HSCs but to   
optimize bone strength and body support. To overcome the   
reduced ability to support HSCs in an open BM cavity created 
by osteoclasts, BM niches were likely developed by osteo-
blastic cells, vascular endothelial cells, reticular cells, or aggre-
gates  of  these  cells  (Adams  and  Scadden,  2006;  Kiel  and 
Morrison, 2008), or by the products of these cells such as angio-
poietin 1, osteopontin, Cxcl12, and thrombopoietin 1 (Calvi   
et al., 2003; Zhang et al., 2003; Arai et al., 2004; Kiel et al., 
2005; Stier et al., 2005; Adams and Scadden, 2006; Sugiyama 
et al., 2006; Kiel and Morrison, 2008; Lymperi et al., 2010).
Manipulating HSCs in vitro to increase their number likely 
results in reduced stemness because quiescence is essential to 
maintain stem cell function (Cheng et al., 2000; Miyamoto   
et al., 2007). Thus, there is likely an antagonistic relationship   
between expansion and quiescence in HSC expansion. Bone 
mineral density (BMD) decreases with age, as osteoporosis is   
increased by osteoclastic activity (Manolagas and Jilka, 1995;   
Teitelbaum, 2007). Hematopoietic activity also decreases with 
age  (Geiger  and  Rudolph,  2009;  Waterstrat  and  Van  Zant, 
2009), suggesting that bone aging can cause both reduced bone 
mass and reduced hematopoiesis, and that antagonizing osteo-
clasts pharmacologically could promote increased bone mass and 
stimulate an induced niche in vivo to increase the HSC pool.
MATERIALS AND METHODS
Mice. op/op, c-Fos–deficient, and RANKL-deficient mice were generated by 
crossing heterozygotes of respective genotypes. c-Fos-deficient mice were pro-
vided by E. Wagner (Institute of Molecular Biotechnology of the Austrian 
Academy of Sciences, Vienna, Austria). Animals were maintained under patho-
gen-free conditions in animal facilities certified by the Keio University School 
of Medicine animal care committee. To analyze blood counts, peripheral blood 
from the postorbital vein was collected in heparinized microtubes (Drummond 
Scientific). 5-FU (Kyowa Hakko Kirinn) was administered intravenously at 
150 mg/kg to 8–12-wk-old op/op, c-Fos–deficient, or littermate control mice 
once a week, and mouse survival was monitored daily. Animal protocols were 
approved by the Keio University School of Medicine animal care committee.
Analysis of skeletal morphology. 8–12-wk-old mice were necropsied, 
and their hindlimbs were removed, fixed in 70% ethanol, and subjected to 
dual energy x-ray absorptiometry analysis to measure BMD and for micro-
radiographic analysis. BMD was shown in 20 longitudinal divisions of femurs.
Mobilization of hematopoietic progenitors. To induce HSPC mobiliza-
tion, mice were injected with recombinant human G-CSF (Kyowa Hakko 
Kirin Co.; 250 µg/kg/d for 5 d, subcutaneous injection). Peripheral blood was 
harvested 3 h after the last G-CSF injection and used for blood counts, deter-
mination of colony-forming units in culture (CFU-C), and flow cytometric 
(FACS) analysis. Blood counts were analyzed using CellTac (Nihon Kohden). 
For CFU-C assays, cells were cultured in methylcellulose medium containing 
recombinant mouse (rm) stem cell factor, rm IL-3, recombinant human (rh) JEM Vol. 208, No. 11  2181
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